Targeting resistant lesions in advanced prostate cancer to improve treatment outcomes
Official title: Project 3: Extending Clinical Benefit by Selective Treatment of Resistant Lesions in mCRPC
Funded at University of Wisconsin-Madison · NIH-10899413 · Data updated 2026-11-12
This study is looking at men with advanced prostate cancer who are not responding well to their current treatments, and it aims to find and target the stubborn areas of cancer that aren't improving, using special imaging and focused radiation therapy to help make the overall treatment more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $348,447 |
| NIH project number | 5P50CA269011-02 |
| Project ID | NIH-10899413 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who are experiencing disease progression but still have responding lesions.
✕Less likely to help
Patients who do not have metastatic castration-resistant prostate cancer or those whose disease is not progressing may not benefit from this research.
What this research studies
This research focuses on men with metastatic castration-resistant prostate cancer (mCRPC) who are experiencing disease progression despite ongoing treatment. The study aims to identify specific lesions that have developed resistance to therapy while the majority of lesions continue to respond. By using advanced imaging techniques, researchers will selectively treat these resistant lesions with localized ablative therapies, such as stereotactic body radiation therapy, to potentially extend the effectiveness of existing systemic treatments. The approach involves detailed imaging assessments and modeling to optimize treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes and prolonged survival for patients with advanced prostate cancer.
How similar studies have gone: Previous research has shown promise in using localized therapies for resistant lesions, indicating potential for success with this novel approach.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Jeraj, Robert — University of Wisconsin-Madison
- Study coordinator: Jeraj, Robert
Related research
Other NIH-funded projects on the same topics.
-
Dual Targeting of B7-H3 in metastatic prostate cancer
A Johns Hopkins team is testing two targeted therapies against B7-H3 to help people with metastatic castration-resistant prostate cancer feel better and show tumor responses.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Extending Benefit by Targeting Resistant Lesions in mCRPC
A cancer center plans to identify on-treatment resistant spots in men with metastatic castration-resistant prostate cancer and then use targeted local therapy to those spots while systemic treatment continues.
-
CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer
A phase 2 study tests whether adding SX-682 to enzalutamide helps men with advanced prostate cancer that no longer responds to abiraterone.
-
Multidimensional approach to boost PSMA-RPT success in advanced prostate cancer
A cancer research grant aims to better understand why PSMA-targeted radiopharmaceutical therapy works sometimes but not always for advanced prostate cancer, with the goal of making treatments more effective for patients who need them.
-
Targeted radiation approach for prostate cancer without continuous castration
A study testing a targeted radiation plan for men with metastatic castration-resistant prostate cancer to improve outcomes and quality of life by avoiding continuous castration for those receiving PSMA-directed therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.